Published in J Clin Microbiol on November 01, 2002
Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One (2012) 2.41
The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department. J Acquir Immune Defic Syndr (2008) 1.94
Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol (2005) 1.77
More and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS Med (2011) 1.74
Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol (2006) 1.64
Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol (2005) 1.35
Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. J Acquir Immune Defic Syndr (2009) 1.34
Dual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers. PLoS One (2011) 1.20
Comparison of the avidity index method and the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV infections. J Clin Microbiol (2005) 1.20
Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS (2011) 1.16
Development of fully automated determination of marker-specific immunoglobulin G (IgG) avidity based on the avidity competition assay format: application for Abbott Architect cytomegalovirus and Toxo IgG Avidity assays. J Clin Microbiol (2009) 1.07
Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS One (2015) 1.04
Avidity Index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Microbiol (2011) 1.03
Comparison of the human immunodeficiency virus (HIV) type 1-specific immunoglobulin G capture enzyme-linked immunosorbent assay and the avidity index method for identification of recent HIV infections. J Clin Microbiol (2007) 0.96
Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002. J Clin Microbiol (2005) 0.92
HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. BMC Infect Dis (2012) 0.90
Low proportion of recent human immunodeficiency virus (HIV) infections among newly diagnosed cases of HIV infection as shown by the presence of HIV-specific antibodies of low avidity. J Clin Microbiol (2005) 0.90
The effect of sample handling on cross sectional HIV incidence testing results. PLoS One (2011) 0.90
A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assay. J Clin Microbiol (2011) 0.89
Molecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, Rwanda. PLoS One (2012) 0.85
HIV infection among illegal migrants, Italy, 2004-2007. Emerg Infect Dis (2009) 0.83
Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. BMC Infect Dis (2012) 0.82
Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. Springer Semin Immunopathol (2006) 0.81
Misclassification of recent HIV-1 seroconversion in sub-Saharan Africa using the sensitive/less sensitive technique. Virol J (2011) 0.80
Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns. PLoS One (2013) 0.79
Incidence of recent human immunodeficiency virus infection at two voluntary counseling testing centers in Pernambuco, Brazil, from 2006 to 2009. J Clin Microbiol (2012) 0.79
Current and future assays for identifying recent HIV infections at the population level. Med Sci Monit (2011) 0.78
Estimation of HIV incidence in two Brazilian municipalities, 2013. Rev Saude Publica (2016) 0.77
HIV Incidence Estimates Using the Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014. PLoS One (2016) 0.77
Modification of AxSYM Human Immunodeficiency Virus Assay to Identify Recent Human Immunodeficiency Virus Infections in Korean Human Immunodeficiency Virus-Positive Individuals. Osong Public Health Res Perspect (2015) 0.75
The Recency Period for Estimation of Human Immunodeficiency Virus Incidence by the AxSYM Avidity Assay and BED-Capture Enzyme Immunoassay in the Republic of Korea. Osong Public Health Res Perspect (2014) 0.75
Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis. Eur J Clin Microbiol Infect Dis (2015) 0.75
Surveillance of recent HIV infections among newly diagnosed HIV cases in Germany between 2008 and 2014. BMC Infect Dis (2017) 0.75
VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE. Biochemistry (1964) 11.48
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr (1999) 2.28
Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. J Clin Microbiol (1997) 2.22
Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-1998: application of the serologic testing algorithm for recent HIV seroconversion. Am J Epidemiol (2001) 2.22
Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin Exp Immunol (1996) 1.90
Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses (2001) 1.81
Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. AIDS Res Hum Retroviruses (2001) 1.44
Antibody avidity following varicella-zoster virus infections. J Med Virol (1991) 1.44
Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J Med Virol (1994) 1.41
Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J Med Virol (2000) 1.35
Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors. AIDS (2002) 1.27
Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis (1997) 1.24
Detection of IgM and IgA HIV antibodies after removal of IgG with recombinant protein G. J Immunol Methods (1990) 1.13
Use of immunoglobulin G antibody avidity for differentiation of primary human herpesvirus 6 and 7 infections. J Clin Microbiol (2001) 1.05
What a test for recent infection might reveal about HIV incidence in England and Wales. AIDS (2000) 0.98
Relative functional affinity of specific anti-core IgG in different categories of hepatitis B virus infection. J Med Virol (1997) 0.95
[Antibody avidity: use for the diagnosis of HIV early infection]. Ann Biol Clin (Paris) (2001) 0.85
[Dynamic study of anti-HIV antibody avidity after cellular immunity restoration under antiretroviral treatment]. Ann Biol Clin (Paris) (2001) 0.84
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84
An autochthonous case of Zika due to possible sexual transmission, Florence, Italy, 2014. Euro Surveill (2016) 2.79
Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature (2006) 2.61
Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr (2004) 2.22
Chikungunya virus in North-Eastern Italy: a seroprevalence survey. Am J Trop Med Hyg (2010) 1.94
Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis (2010) 1.85
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis (2004) 1.85
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr (2003) 1.74
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther (2004) 1.65
Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials (2002) 1.65
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med (2002) 1.59
Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther (2005) 1.58
Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation (2005) 1.52
Human herpesvirus 8 epidemiology: what we do and do not know. AIDS (2003) 1.49
Transmission of hemagglutinin D222G mutant strain of pandemic (H1N1) 2009 virus. Emerg Infect Dis (2010) 1.47
Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis (2007) 1.44
Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child (2011) 1.42
Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer (2007) 1.40
Evaluation of bilirubin concentration in hemolysed samples, is it really impossible? The altitude-curve cartography approach to interfered assays. Clin Chim Acta (2011) 1.38
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. J Chromatogr Sci (2008) 1.33
Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. J Acquir Immune Defic Syndr (2003) 1.33
Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med (2012) 1.32
A method for the direct evaluation of the fatty acid status in a drop of blood from a fingertip in humans: applicability to nutritional and epidemiological studies. Anal Biochem (2004) 1.30
High-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania. PLoS One (2008) 1.30
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Antimicrob Agents Chemother (2011) 1.24
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis (2005) 1.23
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis (2008) 1.22
Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol (2006) 1.22
Risk factors for classical Kaposi's sarcoma. J Natl Cancer Inst (2002) 1.18
HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta (2011) 1.18
An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit (2008) 1.18
Validation of an enzyme-linked immunosorbent assay for diagnosis of human trichinellosis. Clin Vaccine Immunol (2008) 1.17
Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr (2003) 1.15
Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann Nutr Metab (2009) 1.15
Early and late mortality in elderly patients after hip fracture: a cohort study using administrative health databases in the Lazio region, Italy. BMC Geriatr (2011) 1.13
Primary human herpesvirus 8 infection in immunocompetent children. JAMA (2002) 1.13
Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Hum Immunol (2012) 1.13
Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis (2006) 1.13
Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit (2004) 1.12
Experimental studies of susceptibility of Italian Aedes albopictus to Zika virus. Euro Surveill (2016) 1.12
Dengue and chikungunya: long-distance spread and outbreaks in naïve areas. Pathog Glob Health (2014) 1.11
Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma (2008) 1.11
Can we use the pharmacy data to estimate the prevalence of chronic conditions? a comparison of multiple data sources. BMC Public Health (2011) 1.11
Biological properties of olive oil phytochemicals. Crit Rev Food Sci Nutr (2002) 1.10
Detection of Toscana virus central nervous system infections in Sardinia Island, Italy. J Clin Virol (2007) 1.10
Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS (2006) 1.09
Human infection with highly pathogenic A(H7N7) avian influenza virus, Italy, 2013. Emerg Infect Dis (2014) 1.09
Human papillomavirus DNA testing by PCR-ELISA and hybrid capture II from a single cytological specimen: concordance and correlation with cytological results. J Clin Virol (2002) 1.09
Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002. AIDS (2005) 1.07
The HIV type 1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries. AIDS Res Hum Retroviruses (2008) 1.07
Severe acute respiratory syndrome coronavirus sequence characteristics and evolutionary rate estimate from maximum likelihood analysis. J Virol (2004) 1.07
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol (2011) 1.04
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev (2011) 1.04
Determination of serum holotranscobalamin concentrations with the AxSYM active B(12) assay: cut-off point evaluation in the clinical laboratory. Clin Chem Lab Med (2010) 1.04
Louseborne Relapsing Fever in Young Migrants, Sicily, Italy, July-September 2015. Emerg Infect Dis (2016) 1.04
Avidity Index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Microbiol (2011) 1.03
Epidemiological history and phylogeography of West Nile virus lineage 2. Infect Genet Evol (2013) 1.03
Crimean-Congo hemorrhagic fever, southwestern Bulgaria. Emerg Infect Dis (2009) 1.03
The effect of cardiovascular and osteoarticular diseases on disability in older Italian men and women: rationale, design, and sample characteristics of the Progetto Veneto Anziani (PRO.V.A.) study. J Am Geriatr Soc (2002) 1.03
Origin, evolution, and phylogeography of recent epidemic CHIKV strains. Infect Genet Evol (2012) 1.02
Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine (2011) 1.02
Decline of CD4⁺ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. AIDS (2011) 1.01
SARS epidemic in the press. Emerg Infect Dis (2004) 1.01
NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol (2002) 1.01
Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. Health Policy (2005) 1.00
Chikungunya and dengue viruses in travelers. Emerg Infect Dis (2008) 1.00
Phylogeography and epidemiological history of West Nile virus genotype 1a in Europe and the Mediterranean basin. Infect Genet Evol (2011) 1.00
Viral causes of influenza-like illness: Insight from a study during the winters 2004-2007. J Med Virol (2009) 1.00
Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids (2003) 1.00
Prevalence of hepatitis C virus (HCV) genotypes and increase of type 4 in central Italy: an update and report of a new method of HCV genotyping. Anticancer Res (2007) 1.00
Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. J Acquir Immune Defic Syndr (2003) 0.99
An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users. J Hepatol (2005) 0.99
Protective activity of tomato products on in vivo markers of lipid oxidation. Eur J Nutr (2003) 0.99
Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy. Ann Ist Super Sanita (2010) 0.99
Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol (2008) 0.99
Chikungunya and the nervous system: what we do and do not know. Rev Med Virol (2009) 0.98
An outbreak of Q fever in Bulgaria. Ann Ist Super Sanita (2009) 0.98
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria. AIDS Res Hum Retroviruses (2008) 0.98
The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses (2004) 0.98